IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

Zacks Investment Research • Aug 5, 2026

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first quarter of 2026. The Company also advanced multiple regulatory and clinical programs across its immunotherapy pipeline while achieving its eighth consecutive quarter of.

Business Wire • Aug 4, 2026

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago.

Zacks Investment Research • Aug 4, 2026

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio Inc.'s (NASDAQ:IBRX) immunotherapy drug, ANKTIVA.

Benzinga • Jul 30, 2026

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA® (nogapendekin alfa inbakicept) across two indications. The authorization covers ANKTIVA 0.4 mg in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC, and ANKTIVA 1.2 mg in combination wit.

Business Wire • Jul 29, 2026

ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)

ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC and shows promise across broader oncology indications. IBRX's valuation now reflects significant future revenue; rapid share appreciation and anticipated dilution temper near-term upside despite robust revenue ramp and pipeline catalysts. Anktiva's combination with BCG outperforms competitors, with 84% CR in BCG-naïve NMIBC and potential label expansion pending FDA decision in early 2027.

Seeking Alpha • Jul 20, 2026

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks.

Seeking Alpha • Jul 17, 2026

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now

Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.

Benzinga • Jul 13, 2026

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

24/7 Wall Street • Jul 10, 2026

ImmunityBio: A Long-Term Bull Case Worth Watching

ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.

Seeking Alpha • Jul 7, 2026